ADAR1 Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

ADAR1 Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.1M	Sell	136,158 -75,292	-36%	-$6.81M	0.69%	33
2026 Q1	$18.4M	Buy	211,450 +160,101	+312%	+$15.6M	1.08%	19
2025 Q4	$5.5M	Buy	51,349 +1,778	+4%	+$189K	0.4%	55
2025 Q3	$5.01M	Buy	49,571 +4,181	+9%	+$388K	0.47%	48
2025 Q2	$2.87M	Buy	45,390 +8,500	+23%	+$520K	0.44%	46
2025 Q1	$1.95M	Buy	36,890 +5,949	+19%	+$330K	0.36%	59
2024 Q4	$1.73M	Buy	+30,941	New	+$1.71M	0.35%	55
2024 Q3	–	Sell	-13,000	Closed	-$534K	–	332
2024 Q2	$534K	Buy	13,000 +600	+5%	+$23.9K	0.1%	96
2024 Q1	$537K	Buy	+12,400	New	+$543K	0.12%	78

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ADAR1 Capital Management's RYTM Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 36% in Q2 2026, selling an estimated $6.81M and leaving 136,158 shares worth $15.1M. The position accounts for 0.69% of the portfolio, ranked #33.

ADAR1 Capital Management first reported a position in RYTM in Q1 2024 and has held it in 9 quarters since. The position peaked at $18.4M in Q1 2026. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

ADAR1 Capital Management held 136,158 shares of Rhythm Pharmaceuticals worth $15.1M as of Q2 2026.
ADAR1 Capital Management sold 75,292 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $6.81M.
Rhythm Pharmaceuticals made up 0.69% of ADAR1 Capital Management's portfolio in Q2 2026, its #33 holding.
ADAR1 Capital Management first reported a position in Rhythm Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
ADAR1 Capital Management's Rhythm Pharmaceuticals position peaked at $18.4M in Q1 2026.
302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.